Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS.

ALS-SOD1 - Voyager

Cu(II)ATSM - Collaborative Medicinal Development

riluzole - Generic mfg.

http://www.ncbi.nlm.nih.gov/pubmed/37317638

Claire E Shepherd; Dominic Rowe; Glenda M Halliday; Heather McCann; Jillian J Kril; Matthew C Kiernan; Rachel H Tan; Yue Yang

Jun 16, 2023